Robert Paull co-founded Lux Capital in 2000 with Peter Hébert and Josh Wolfe and also co-founded Lux Research. He was the founding CEO of Harvard Medical School spinout Genocea Biosciences and the founding CEO, president and treasurer of Johns Hopkins spinout Kala Pharmaceuticals, and later served as CEO of Mahana Therapeutics from 2018 to 2020. Lux Capital's site lists him under its advisors as Co-Founder and Venture Partner focused on healthcare, managing the firm's investments in Cala Health, Kala Pharmaceuticals, Kyruus and Visterra. He has served on the board of directors of KALA BIO since July 2009 and has advised the Bill and Melinda Gates Foundation.
Education
B.S. Architecture, University of Virginia
Previous Experience
Co-Founder, Lux Research
Founding CEO, Genocea Biosciences
Founding CEO, President and Treasurer, Kala Pharmaceuticals
CEO, Mahana Therapeutics
Notable Investments
Kala Pharmaceuticals KALACala HealthKyruusVisterra
Board Seats
KALA BIO
Career Timeline
2000
Co-founded Lux Capital with Peter Hébert and Josh Wolfe.
2006
Became founding CEO of Harvard Medical School spinout Genocea Biosciences, serving until 2009.
2009
Founded Johns Hopkins spinout Kala Pharmaceuticals, served as its founding CEO, president and treasurer until 2012, and joined its board in July 2009.
2014
Became a venture partner at Lux Capital, focusing on healthcare.
2018
Became CEO of Mahana Therapeutics, serving until 2020.